These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23960879)

  • 21. Evaluation of the Effect of Intravitreal Bevacizumab (Avastin) in Patients with Diabetic Macular Edema.
    Pawan P; Joshi P; Pradhan E; Subedi P
    Nepal J Ophthalmol; 2020 Jul; 12(24):236-244. PubMed ID: 33978618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of macular serous neuroretinal detachment in tilted disk syndrome: report of 3 cases.
    Donati MC; Miele A; Abbruzzese G; Giuntoli M; Giansanti F; Menchini U
    Eur J Ophthalmol; 2013; 23(2):267-70. PubMed ID: 23225087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
    Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.
    Lim JW; Ryu SJ; Shin MC
    Korean J Ophthalmol; 2010 Jun; 24(3):155-8. PubMed ID: 20532141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.
    Sakalar YB; Keklikci U; Unlu K; Alakus MF; Kara IH
    Curr Ther Res Clin Exp; 2010 Jun; 71(3):173-85. PubMed ID: 24683263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the efficacy of photodynamic therapy in patients with chronic central serous chorioretinopathy.
    Manethová K; Ernest J; Hrevuš M; Jirásková N
    Cesk Slov Oftalmol; 2020; 75(6):298-308. PubMed ID: 32911945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
    Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
    Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study.
    Tekin K; Sekeroglu MA; Cankaya AB; Teke MY; Doguizi S; Yilmazbas P
    Semin Ophthalmol; 2018; 33(2):265-270. PubMed ID: 27841949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spironolactone in the treatment of central serous chorioretinopathy - a case series.
    Herold TR; Prause K; Wolf A; Mayer WJ; Ulbig MW
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1985-91. PubMed ID: 25138605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
    Li L; Yuan F; Xu GZ; Wang WJ
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transpupillary thermotherapy for atypical central serous chorioretinopathy.
    Kawamura R; Ideta H; Hori H; Yuki K; Uno T; Tanabe T; Tsubota K; Kawasaki T
    Clin Ophthalmol; 2012; 6():175-9. PubMed ID: 22331974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretreatment clinical variables associated with the response to intravitreal bevacizumab (Avastin) injection in patients with persistent diabetic macular edema.
    Warid Al-Laftah FA; Elshafie M; Alhashimi M; Pai A; Farouq M
    Saudi J Ophthalmol; 2010 Oct; 24(4):133-8. PubMed ID: 23960890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab.
    Altun A; Kurna SA; Olcaysu OO; Sengor T; Aki SF; Atakan TG
    J Ocul Pharmacol Ther; 2014 Dec; 30(10):842-6. PubMed ID: 25216333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective Retina Therapy in Acute and Chronic-Recurrent Central Serous Chorioretinopathy.
    Framme C; Walter A; Berger L; Prahs P; Alt C; Theisen-Kunde D; Kowal J; Brinkmann R
    Ophthalmologica; 2015; 234(4):177-88. PubMed ID: 26368551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bullous Variant of Central Serous Chorioretinopathy: Expansion of Phenotypic Features Using Multimethod Imaging.
    Balaratnasingam C; Freund KB; Tan AM; Mrejen S; Hunyor AP; Keegan DJ; Dansingani KK; Dayani PN; Barbazetto IA; Sarraf D; Jampol LM; Yannuzzi LA
    Ophthalmology; 2016 Jul; 123(7):1541-52. PubMed ID: 27084564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.